Key result
Niclosamide inhibited the replication of SARS-CoV, totally abolishing viral antigen synthesis at a concentration of 1.56 microM.
Why the study?
Does niclosamide inhibit replication of SARS-CoV?
Does niclosamide inhibit replication of SARS-CoV?
Niclosamide demonstrates in vitro efficacy in inhibiting SARS-CoV replication, suggesting potential as an antiviral candidate.
Antiviral agents are urgently needed to fight severe acute respiratory syndrome (SARS). We showed that niclosamide, an existing antihelminthic drug, was able to inhibit replication of a newly discovered coronavirus, SARS-CoV; viral antigen synthesis was totally abolished at a niclosamide concentration of 1.56 microM, as revealed by immunoblot analysis. Thus, niclosamide represents a promising drug candidate for the effective treatment of SARS-CoV infection.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2004) studied Severe acute respiratory syndrome (SARS). Niclosamide was evaluated on Viral antigen synthesis. Niclosamide inhibited the replication of SARS-CoV, totally abolishing viral antigen synthesis at a concentration of 1.56 microM.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: